Any current/future new fundraising through debt or equity?

There is no explicit mention of any current or planned fundraising through debt or equity in the provided transcript. The company highlights that it is not capital-intensive and operates on a project-based model. Expansion is supported through internal efficiencies and incremental equipment purchases rather than large capex. The only constraint mentioned regarding growth is working capital, specifically receivables, which they aim to improve. No direct statements about raising capital or issuing equity or debt were made.

Any current/future capex/capital investment/strategic investment?

Fabtech Technologies Limited is not a capital-intensive business; it operates on a project-based model. Current manufacturing capacities support their expansion plans without immediate need for large capex. To double revenues, the company would increase equipment purchases proportionally (X plus Y) but can leverage the existing team for higher efficiency. No recent significant capital expansion on manufacturing or recruitment; focus is on internal efficiency improvements. Working capital, especially receivables, is a potential constraint rather than fixed capital investment. Recently signed a

Future growth expectations in sales/revenue/volumes?

Fabtech aims for sustained revenue growth of 20-25% year-on-year, as indicated by management. Order book growth is steady, with a recent 7-9% increase in the order pipeline between July and September 2025. Projects typically have an 18-24 month execution cycle, suggesting stable revenue visibility over the medium term. The company expects to maintain or improve EBITDA margins sustainably, focusing on structural efficiencies. Expansion plans rely on improving internal efficiencies rather than heavy capex; existing manufacturing and team capacity can support growth. Growth is supported by strong

Future growth expectations in earnings/operating earnings/profits/EPS?

Fabtech Technologies aims for sustained growth of 20-25% year-on-year in revenue, supported by a strong and growing order book (~INR 904 crores as of July 2025 with ~9% growth by September 2025). Operating margins have shown improvement, with EBITDA margins increasing from around 12-15% historically to approximately 25% recently; management focuses on sustaining and growing these margins without overcommitting. Profitability growth is linked to structural efficiencies driven by procurement, sales, and high-margin capex projects. The company operates on a yearly guidance model, with lumpy quart

Current/ Expected Orderbook/ Pending Orders?

As of July 2025, the order book stood at INR 904.41 crore. By September 2025, the order book grew by approximately 7% to 9%. The execution plan for projects typically spans 18 to 24 months, covering concept, design, supply chain, and execution. Secured 20 projects worth INR 137 crore, with an average project completion of about 65%. The company anticipates sustained growth in the order book with a quarterly growth rate of around 9%. There is an ongoing "hot pipeline" of projects under negotiation and submission. The focus remains on converting the strong pipeline in pharmaceutical emerging mar

Fabtech Technologies LtdQ2 FY26Healthcare Services

Fabtech Technologies Ltd Q2 FY26 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹123.9P/E: 11.3Market Cap: ₹552 CrSector: Healthcare Services

Management growth scorecard

Revenue

Category 2

Margin

Category 3

Fundraise

N/A

Order

Yes

Capex

1 of 4 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 2

Fabtech aims for sustained revenue growth of 20-25% year-on-year, as indicated by management.
Order book growth is steady, with a recent 7-9% increase in the order pipeline between July and September 2025.
Projects typically have an 18-24 month execution cycle, suggesting stable revenue visibility over the medium term.
The company expects to maintain or improve EBITDA margins sustainably, focusing on structural efficiencies.
Expansion plans rely on improving internal efficiencies rather than heavy capex; existing manufacturing and team capacity can support growth.
Growth is supported by strong demand in emerging pharmaceutical markets, especially in MENA, GCC, and ECO zones.
The company is focused on medicinal independence trends, aiding new project pipelines and diversified product portfolios.
Management targets continuous over-performance each year, without over-committing on specific growth numbers.

Margin guidance

Category 3

Fabtech Technologies aims for sustained growth of 20-25% year-on-year in revenue, supported by a strong and growing order book (~INR 904 crores as of July 2025 with ~9% growth by September 2025).
Operating margins have shown improvement, with EBITDA margins increasing from around 12-15% historically to approximately 25% recently; management focuses on sustaining and growing these margins without overcommitting.
Profitability growth is linked to structural efficiencies driven by procurement, sales, and high-margin capex projects.
The company operates on a yearly guidance model, with lumpy quarterly results but a goal to consistently outperform previous quarters and years.
Working capital management is improving, aiming to reduce receivable cycles incrementally.
No concrete medium-term EPS guidance was provided, but overall growth and profitability targets imply positive earnings trajectory over next 2-3 years.

See what Fabtech Technologies Ltd management said on margin guidance — free account, 30 seconds.

Fundraise plans

There is no explicit mention of any current or planned fundraising through debt or equity in the provided transcript.
The company highlights that it is not capital-intensive and operates on a project-based model.
Expansion is supported through internal efficiencies and incremental equipment purchases rather than large capex.
The only constraint mentioned regarding growth is working capital, specifically receivables, which they aim to improve.
No direct statements about raising capital or issuing equity or debt were made.

Order book

Yes

As of July 2025, the order book stood at INR 904.41 crore.
By September 2025, the order book grew by approximately 7% to 9%.
The execution plan for projects typically spans 18 to 24 months, covering concept, design, supply chain, and execution.
Secured 20 projects worth INR 137 crore, with an average project completion of about 65%.
The company anticipates sustained growth in the order book with a quarterly growth rate of around 9%.
There is an ongoing "hot pipeline" of projects under negotiation and submission.
The focus remains on converting the strong pipeline in pharmaceutical emerging markets, mainly Middle East, Africa, and GCC regions.

See what Fabtech Technologies Ltd management said on order book — free account, 30 seconds.

Capex plans

Fabtech Technologies Limited is not a capital-intensive business; it operates on a project-based model.
Current manufacturing capacities support their expansion plans without immediate need for large capex.
To double revenues, the company would increase equipment purchases proportionally (X plus Y) but can leverage the existing team for higher efficiency.
No recent significant capital expansion on manufacturing or recruitment; focus is on internal efficiency improvements.
Working capital, especially receivables, is a potential constraint rather than fixed capital investment.
Recently signed a positive MOU with KP Group to explore sustainable energy projects, aiming to broaden service offerings and incorporate sustainable solutions in current and future projects.
Overall, capital investments are incremental and aligned with project needs and growth rather than large-scale capex.

Track Fabtech Technologies Ltd — get its next earnings analysis in your feed

How does Fabtech Technologies Ltd rank vs peers in Healthcare Services?

Pro feature

ThisFabtech Technologies Ltd

Rev 2Mar 3

See where Fabtech Technologies Ltd sits in Healthcare ServicesSee which companies these are, and every other name in the sector.Open rankings

How does Fabtech Technologies Ltd rank in Healthcare Services?

Compare Fabtech Technologies Ltd against every Healthcare Services company (Q2 FY26) on revenue, margins and earnings-call signals.

View Healthcare Services leaderboard →

What Fabtech Technologies Ltd's management said in earlier quarters

Others in Healthcare Services this season

Narayana Hrudayalaya Ltd (Q2 FY27)
Consolidated operating revenue for Q2 FY27: ₹28,440 Mn, up 73.0% YoY (Page 15, 16). Key investor presentation takeaways from Narayana Hrudayalaya Ltd's Q2 FY27
Artemis Medicare Services Ltd (Q2 FY27)
Q2 FY27 consolidated revenue from operations: INR 31,104 Lacs, up 13.2% YoY (Page 39, 40, 20). Key investor presentation takeaways from Artemis Medicare Service
Max Healthcare Institute Ltd (Q2 FY27)
Q2 FY27 Gross Revenue: ₹3,219 Cr, up 20% YoY (Page 4, 17) . Key investor presentation takeaways from Max Healthcare Institute Ltd's Q2 FY27 investor presentatio
Indegene Ltd (Q2 FY27)
Revenue from operations for Q2 FY27: INR 11,223 million, up 39.5% YoY (Page 23, 15, 4) . Key investor presentation takeaways from Indegene Ltd's Q2 FY27 investo

Compare:vs Apollo Hospitals Enterprise Ltd vs Manipal Health Enterprises Ltd vs Max Healthcare Institute Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →